Skip to main content
. Author manuscript; available in PMC: 2023 Aug 25.
Published in final edited form as: Adv Res Gastroenterol Hepatol. 2021 Sep 30;17(5):555972. doi: 10.19080/argh.2021.17.555972

Table 2:

Characteristics of stage II/III rectal adenocarcinoma patients by receipt of guideline-recommended surveillance procedures during the 14-month post-treatment surveillance period, row %.

Received ≥1 Colonoscopy Received ≥2 Physician Received
≥2 CEA
test
Received
≥2 CT
tests
Characteristic N (%) No
n=464
Yes
n=560
P-value No
n=472
Yes
n=552
P-value No
n=546
Yes
n=478
P-value No
n=815
Yes
n=209
P-value
Age 66-70 241 (24) 32 68 <0.0001 42.7 57.3 <0.0001 46.5 53.5 <0.0001 72.2 27.8 <0.0001
>70-75 229 (22) 38.4 61.6 38.4 61.6 41.9 58.1 70.3 29.7
>75-80 216 (21) 37.5 62.5 39.8 60.2 51.8 48.2 84.7 15.3
>80 338 (33) 64.5 35.5 57.7 42.3 66.9 33.1 87.9 12.1
Gender Male 549 (54) 46.7 53.3 0.3944 44.4 55.6 0.3179 52.8 47.2 0.7754 82.5 17.5 0.0301
Female 475 (46) 44.1 55.9 47.5 52.5 53.7 46.3 77 23
Marital status Not married1 511 (50) 53.6 46.4 <0.0001 52.6 47.4 <0.0001 60.3 39.7 <0.0001 83 17 0.0073
Married 513 (50) 37 63 39.6 60.4 46.4 53.6 76.2 23.8
Race Other/Unknown 148 (14) 50 50 0.2155 56.8 43.2 0.0049 57.4 42.6 0.2783 82.4 17.6 0.3536
White 876 (86) 44.5 55.5 44.3 55.7 52.6 47.4 79.1 20.9
Rural status Rural 221 (22) 48.4 51.6 0.2952 45.7 54.3 0.6331 52.3 47.7 0.214 80.5 19.5 0.1939
Urban1 803 (78) 44.5 55.5 47.5 52.5 57 43 76.5 23.5
Living below Above median 489 (48) 47 53 0.2898 49.5 50.5 0.0372 56.2 43.8 0.0737 80.6 19.4 0.4557
poverty indicator Below median 535 (52) 43.7 56.3 43 57 50.7 49.3 78.7 21.3
With college Above median 540 (53) 43.9 56.1 0.3337 46.1 53.9 0.9906 52.8 47.2 0.7132 79.6 20.4 0.9734
Education Below median 484 (47) 46.9 53.1 46.1 53.9 53.9 46.1 79.6 20.4
Stage II 598 (58) 45.1 54.9 0.9018 45.3 54.7 0.555 53.7 46.3 0.7852 78.8 21.2 0.4634
III 426 (42) 45.5 54.5 47.2 52.8 52.8 47.2 80.8 19.2
Charlson score 0 543 (53) 41.2 58.8 0.0009 42.5 57.5 0.006 48.2 51.8 <0.0001 77.3 22.7 0.0464
1 274 (27) 44.9 55.1 46 54 52.9 47.1 79.6 20.4
2+ 207 (20) 56.5 43.5 55.6 44.4 0.0378 67.1 32.9 85.5 14.5
Function-Related 0 665 (65) 42.6 57.4 0.0016 43.8 56.2 50.3 49.7 <0.0001 77 23 0.0212
indicator 1 211 (21) 44.3 55.7 46.7 53.3 53.8 46.2 84.3 15.7
2+ 148 (14) 58.8 41.2 55.4 44.6 <0.0001 66.2 33.8 84.5 15.5
CRT sequence received No CRT 360 (25) 57.2 42.8 <0.0001 59.4 40.6 73.1 26.9 <0.0001 91.7 8.3 <0.0001
Neoadjuvant CRT + Adjuvant Chemo 211 (27) 31.8 68.2 30.8 69.2 29.9 70.1 67.8 32.2
Neoadjuvant CRT 226 (25) 44.7 55.3 42.9 57.1 47.8 52.2 77 23
Adjuvant CRT only 69 (8) 23.2 76.8 36.2 63.8 40.6 59.4 62.3 37.7
Other 158 (15) 46.8 53.2 44.9 55.1 53.2 46.8 79.1 20.9
Surgical No 706 (69) 43.1 56.9 0.0309 42.6 57.4 0.0009 49.3 50.7 0.0001 79 21 0.513
complications Yes 318 (31) 50.3 49.7 53.8 46.2 62.3 37.7 80.8 19.2
Surgeon volume2 High volume 631 (62) 41.7 58.3 0.012 41 59 <0.0001 47.2 52.8 <0.0001 78 22 0.2657
Low volume 286 (28) 50.7 49.3 52.1 47.9 61.5 38.5 82.2 17.8
Unknown 107 (10) 52.3 47.7 59.8 40.2 67.3 32.7 82.2 17.8
Hospital volume2 High volume 637 (62) 41.3 58.7 0.0032 44.3 55.7 0.2753 49.6 50.4 0.0059 78.3 21.7 0.3526
Low volume 243 (24) 50.6 49.4 50.2 49.8 61.3 38.7 82.7 17.3
Unknown 144 (14) 54.2 45.8 47.2 52.8 56.3 43.7 79.9 20.1
Proximity to 0-15 minutes 277 (27) 37.2 62.8 46.9 53.1 53.8 46.2 80.5 19.5
high-volume >15-30 minutes 169 (16) 49.7 50.3 0.0096 49.7 50.3 0.6823 55.6 44.4 0.9019 85.2 14.8 0.1608
hospital 30+ minutes 293 (29) 45.7 54.3 45.1 54.9 52.6 47.4 76.8 23.2
Unknown 285 (28) 50.2 49.8 44.2 55.8 52.3 47.7 78.3 21.7